Buprenorphine

Major

Buprenorphine Nitrous Oxide Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Nordazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Norfloxacin Explained An increased risk of QT interval prolongation Details Buprenorphine Nortriptyline Explained An increased risk of serotonin syndrome and an increased risk of paralytic ileus Details Buprenorphine Octreotide Bynfezia An increased risk of QT interval prolongation Details Buprenorphine Ofloxacin Floxin® An increased risk of QT interval prolongation Details Buprenorphine Olanzapine Explained An increased risk of QT interval prolongation, an increased risk of CNS and respiratory depression and an increased risk of paraly... Details Buprenorphine Oliceridine Olinvyk Explained Reduced analgesic effect of oliceridine and an increased risk of serotonin syndrome Details Buprenorphine Olodaterol Striverdi Explained An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Buprenorphine Omaveloxolone Skyclarys Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Buprenorphine Ondansetron Explained An increased risk of serotonin syndrome and QT interval prolongation Details Buprenorphine Opipramol Explained An increased risk of serotonin syndrome Details Buprenorphine Opium Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Opium Alkaloids Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Orphenadrine Explained Enhanced neuromuscular blocking action, an increased risk of respiratory depression and CNS depression and an increased risk of pa... Details Buprenorphine Osilodrostat Isturisa Explained Increased risk of QT interval prolongation Details Buprenorphine Osimertinib Tagrisso Explained Increased risk of QT interval prolongation Details Buprenorphine Oxaliplatin Explained Increased risk of QT-interval prolongation Details Buprenorphine Oxazepam Explained An increased risk of CNS depression and respiratory depression Details Buprenorphine Oxcarbazepine Oxtellar Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Oxitropium Bromide Explained An increased risk of paralytic ileus Details Buprenorphine Oxybutynin Ditropan Explained An increased risk of paralytic ileus Details Buprenorphine Oxycodone Oxaydo Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome Details Buprenorphine Oxymorphone Explained Reduced analgesic effect or precipitation of withdrawal symptoms and an increased risk of serotonin syndrome Details Buprenorphine Ozanimod Explained An increased risk of serotonin syndrome or opioid-related toxicity, an increased risk of serious adverse reactions and additive ef... Details Buprenorphine Pacritinib Vonjo® Explained An increased risk of QT interval prolongation Details Buprenorphine Palbociclib Ibrance Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Paliperidone Erzofri Explained An increased risk of CNS depression, an increased risk of QT interval prolongation and torsade de pointes Details Buprenorphine Palonosetron Explained An increased risk of serotonin syndrome Details Buprenorphine Panobinostat Farydak Explained An increased risk of QT interval prolongation Details Buprenorphine Papaveretum Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Papaverine Pavacot® Explained An increased risk of QT interval prolongation Details Buprenorphine Paregoric Explained An increased risk of serotonin syndrome and an increased risk of respiratory and CNS depression Details Buprenorphine Paroxetine Paxil Explained An increased risk of QT interval prolongation, an increased risk of serotonin syndrome and an increased risk of paralytic ileus Details Buprenorphine Pasireotide Signifor Explained An increased risk of QT interval prolongation Details Buprenorphine Pazopanib Votrient Explained An increased risk of QT interval prolongation Details Buprenorphine Pentamidine NebuPent Explained An increased risk of QT interval prolongation Details Buprenorphine Pentazocine Explained Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome and respiratory depr... Details Buprenorphine Pentobarbital Fatal-Plus Explained An increased risk of respiratory depression and CNS depression Details Buprenorphine Perampanel FYCOMPA Explained An increased risk of respiratory depression and CNS depression Details